HPV L1 VLP Purification via Thermal Precipitation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying Human Papillomavirus (HPV) L1 proteins are inefficient and costly, limiting the production of high-purity virus-like particles (VLPs) necessary for cervical cancer vaccines, especially in developing countries, due to high costs and complexity in large-scale production.
Innovation Solution
A method involving the culturing of transformed host cells expressing HPV L1 proteins, disruption of cells, addition of a reducing agent, and subsequent chromatography after heating and chilling the homogenate to enhance protein purity and structural integrity of VLPs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods (sucrose cushion, size-exclusion chromatography, ion exchange chromatography) are used to purify HPV VLPs, then high purity VLPs can be obtained, but the process becomes too complex and costly for large-scale production
Solution Approach 1:
The patent segments the purification process into distinct functional stages: (1) cell disruption and initial clarification, (2) ammonium sulfate precipitation for bulk contaminant removal, (3) heparin affinity chromatography for VLP purification, and (4) final polishing steps. Each stage targets specific contaminants, transforming a single complex purification step into multiple manageable, optimized sub-steps that collectively achieve high purity without excessive complexity
Solution Approach 2:
The patent introduces ammonium sulfate as an intermediary substance that facilitates selective precipitation of contaminant proteins while leaving VLPs in solution. This intermediary reagent enables the separation of VLPs from the majority of host cell proteins through differential solubility, serving as an effective bridge between crude extract and purified VLP product
2Manufacturing precision
If multiple sequential purification steps are performed to increase VLP purity, then manufacturing precision improves, but productivity decreases due to time-consuming repeated dialysis and multiple chromatography steps
Solution Approach 1:
The patent merges the contaminant removal function and VLP purification function into a single integrated heparin chromatography step. By optimizing the chromatography conditions and sample preparation, the process achieves both contaminant elimination and VLP recovery in one operation, eliminating the need for separate dialysis steps that were previously required between purification operations
Solution Approach 2:
The patent employs parameter changes in the chromatography process, including optimization of buffer composition, flow rate, and elution gradients, to maximize both purity and recovery in a single pass. By carefully controlling these parameters, the process achieves high purification factors without requiring multiple sequential steps, thereby maintaining productivity
3Manufacturing precision
If conventional purification methods are used, then VLP purity can be increased, but production costs increase to 80% of total production cost for downstream processing
Solution Approach 1:
The patent employs ammonium sulfate precipitation as a low-cost, simple technique to remove the majority of contaminant proteins before chromatography. This inexpensive preliminary step significantly reduces the load on subsequent chromatography columns, extending their lifetime and reducing the frequency of expensive column replacements while maintaining high final purity
Solution Approach 2:
The patent extracts and removes the bulk of contaminant proteins through ammonium sulfate precipitation before the expensive chromatography step. By taking out the majority of impurities in this preliminary, low-cost step, the subsequent chromatography process deals with a much cleaner sample, requiring less resin capacity and reducing overall processing costs while achieving the same final purity
4Quantity of substance
If HPV L1 protein is produced in Saccharomyces cerevisiae, then vaccine antigen can be produced, but the L1 protein numbers no more than 1% of all homogenate proteins making recovery difficult
Solution Approach 1:
The patent converts the harmful effect of high contaminant levels into a benefit by using ammonium sulfate precipitation conditions specifically optimized to precipitate contaminant proteins while keeping VLPs in solution. The presence of abundant contaminant proteins (which was previously a problem) becomes advantageous as it provides a large contrast in solubility behavior, enabling highly selective precipitation and simplifying the isolation of the rare VLPs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly increases the purity and immunogenicity of HPV L1 proteins, producing VLPs with structural characteristics similar to native HPV virions, thus improving vaccine efficacy and reducing production costs.
Implementation Method 1
adding a reducing agent to a homogenate of the host cells
Implementation Method 2
purifying the HPV L1 proteins by performing chromatography on the homogenate of the host cells to which the reducing agent is added
Implementation Method 3
heating and chilling the homogenate to enhance protein purity and structural integrity of VLPs
Data Source
AI summary
Provided is a method of purifying human papillomavirus (HPV) L1 proteins with high purity and high efficiency. According to the purification method, a purification purity and yield of HPV L1 proteins can be considerably increased when heating/chilling is formed by treating a cell homogenate with a reducing agent. In addition, VLPs of the HPV L1 protein purified by the purification method have excellent antigenicity and immunogenicity.